These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24485094)

  • 41. A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 microg ethinylestradio1/75 microg gestodene (Meliane) and 30 microg ethinylestradio1/75 microg gestodene (Gynera).
    Taneepanichskul S; Kriengsinyot R; Jaisamrarn U
    Contraception; 2002 Dec; 66(6):407-9. PubMed ID: 12499032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current perspectives on combination oral contraceptives.
    Smith MA; Youngkin EQ
    Clin Pharm; 1984; 3(5):485-96. PubMed ID: 6386284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Desogestrel, gestodene contraceptives may carry greater thromboembolic risk.
    Am J Health Syst Pharm; 1996 Feb; 53(3):228. PubMed ID: 8808016
    [No Abstract]   [Full Text] [Related]  

  • 44. Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives--results of isotope dilution mass spectrometry measurements.
    Siekmann L; Siekmann A; Bidlingmaier F; Brill K; Albring M
    Eur J Endocrinol; 1998 Aug; 139(2):167-77. PubMed ID: 9724072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Classification and comparison of oral contraceptives containing new generation progestogens.
    Newton JR
    Hum Reprod Update; 1995 May; 1(3):231-63. PubMed ID: 9187941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of an ethinyl estradiol/gestodene transdermal contraceptive patch on the endometrium: a single-center, uncontrolled study.
    Merz M; Grunert J
    Womens Health (Lond); 2014 Jan; 10(1):37-43. PubMed ID: 24328597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tailoring combination oral contraceptives to the individual woman.
    Archer DF; Lasa IL
    J Womens Health (Larchmt); 2011 Jun; 20(6):879-91. PubMed ID: 21631372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism.
    Bastianelli C; Farris M; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):315-326. PubMed ID: 27977304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gestoden, an innovative progestogen.
    Hoppe G
    Adv Contracept; 1987 Jun; 3(2):159-66. PubMed ID: 3630825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen-free oral hormonal contraception: benefits of the progestin-only pill.
    de Melo NR
    Womens Health (Lond); 2010 Sep; 6(5):721-35. PubMed ID: 21080791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmacology of nomegestrol acetate.
    Ruan X; Seeger H; Mueck AO
    Maturitas; 2012 Apr; 71(4):345-53. PubMed ID: 22364709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Department of health changes advice on third generation pills.
    Mayor S
    BMJ; 1999 Apr; 318(7190):1026. PubMed ID: 10205088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triphasic oral contraceptives: review and comparison of various regimens.
    Cedars MI
    Fertil Steril; 2002 Jan; 77(1):1-14. PubMed ID: 11779584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions.
    van der Burg B; Kalkhoven E; Isbrücker L; de Laat SW
    J Steroid Biochem Mol Biol; 1992 Jun; 42(5):457-65. PubMed ID: 1616875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical profile of contraceptive progestins.
    Benagiano G; Primiero FM; Farris M
    Eur J Contracept Reprod Health Care; 2004 Sep; 9(3):182-93. PubMed ID: 15697108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new oral contraceptive, Femovan.
    Fotherby K
    Adv Contracept; 1987 Dec; 3(4):349-53. PubMed ID: 2965493
    [No Abstract]   [Full Text] [Related]  

  • 57. Hemorheological mechanisms for increased thrombosis in subjects using gestodene.
    Swanepoel AC; Roberts HC; Soma P; Lindeque BG; Bester J
    Microsc Res Tech; 2018 Dec; 81(12):1489-1500. PubMed ID: 30365192
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.
    Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL
    Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs.
    Guengerich FP
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2159-63. PubMed ID: 2256525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [New progestins in oral hormonal contraceptives].
    Runnebaum B; Rabe T
    Arch Gynecol Obstet; 1989; 245(1-4):1000-5. PubMed ID: 2679410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.